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A B S T R A C T
Introduction: Since 2007, HPV vaccine has been available to low and middle income countries (LAMIC) for small-
scale ‘demonstration projects’, or national programmes. We analysed coverage achieved in HPV vaccine de-
monstration projects and national programmes that had completed at least 6 months of implementation between
January 2007–2016.
Methods: A mapping exercise identiﬁed 45 LAMICs with HPV vaccine delivery experience. Estimates of coverage
and factors inﬂuencing coverage were obtained from 56 key informant interviews, a systematic published lit-
erature search of 5 databases that identiﬁed 61 relevant full texts and 188 solicited unpublished documents,
including coverage surveys. Coverage achievements were analysed descriptively against country or project/
programme characteristics. Heterogeneity in data, funder requirements, and project/programme design pre-
cluded multivariate analysis.
Results: Estimates of uptake, schedule completion rates and/or ﬁnal dose coverage were available from 41 of 45
LAMICs included in the study. Only 17 estimates from 13 countries were from coverage surveys, most were
administrative data. Final dose coverage estimates were all over 50% with most between 70% and 90%, and
showed no trend over time. The majority of delivery strategies included schools as a vaccination venue. In
countries with school enrolment rates below 90%, inclusion of strategies to reach out-of-school girls contributed
to obtaining high coverage compared to school-only strategies. There was no correlation between ﬁnal dose
coverage and estimated recurrent ﬁnancial costs of delivery from cost analyses. Coverage achieved during joint
delivery of HPV vaccine combined with another intervention was variable with little/no evaluation of the
correlates of success.
Conclusions: This is the most comprehensive descriptive analysis of HPV vaccine coverage in LAMICs to date. It
is possible to deliver HPV vaccine with excellent coverage in LAMICs. Further good quality data are needed from
health facility based delivery strategies and national programmes to aid policymakers to eﬀectively and sus-
tainably scale-up HPV vaccination.
1. Introduction
Persistent infection with high-risk human papillomavirus (HPV)
genotypes is the cause of almost all cases of cervical cancer and is also
associated with multiple other anogenital and oropharyngeal cancers
[1]. Cervical cancer is the third most common cause of cancer-related
deaths in women in low- and middle-income countries (LAMIC) [2]. In
settings with eﬀective screening programmes, most cervical abnorm-
alities are identiﬁed and treated before they progress to cervical cancer.
In many LAMIC the coverage of screening services is low [3] leading to
women developing advanced stage disease and high cervical cancer
mortality rates. Additionally, HIV, a major problem in many LAMIC,
increases an individual's risk of HPV infection, persistence [4] and
progression to cervical cancer [5–8].
There are currently three prophylactic HPV vaccines. A bivalent
vaccine targets HPV 16 and 18 (Cervarix®), and a quadrivalent vaccine
(Gardasil®) additionally targets HPV 6 and 11 that cause genital warts.
A nonavalent vaccine (Gardasil 9®) has recently been licensed in the US,
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Europe, and other high income countries and targets additional onco-
genic HPV serotypes: 31, 33, 45, 52 and 58. All three vaccines have
proven to be highly eﬃcacious against persistent infection of their
vaccine genotypes and associated cervical intraepithelial neoplasia
[9–11]. The World Health Organisation (WHO) currently recommends
vaccination of 9–13 year olds as vaccination is most eﬀective prior to
sexual debut and ﬁrst exposure to HPV [12]. In 2014, the Strategic
Advisory Group of Experts on Immunisation (SAGE) revised re-
commendations from a schedule of 3 doses [13], to 2 doses given at a
6–12 month interval [14] for girls aged 9–14 years [15,16].
HPV vaccine ﬁrst became available for use in LAMIC in 2007 with
vaccine donations through the GARDASIL® Access Program (GAP) [17],
manufacturer donations, the Bill &Melinda Gates Foundation through
PATH, or other means. Demonstration projects were designed as pilot
projects in small areas of a country to enable experience to be gained in
delivering an expensive, gender-speciﬁc vaccine to, what was in many
countries, a novel target age group [18]. In 2012, Gavi, the Vaccine
Alliance, commenced support for HPV vaccination demonstration pro-
jects or national programmes in 53 Gavi-eligible countries [19]. Gavi
support included some funds for formal evaluation of HPV vaccine
delivery and required a coverage survey, post-introduction evaluation
and costing analysis after the ﬁrst year of implementation.
This paper presents the HPV vaccine coverage achieved in demon-
stration projects and national programmes in LAMIC that had com-
pleted at least six months of implementation between January 2007 and
May 2016. Related publications summarising lessons learnt from HPV
vaccination in 45 LAMICs have not had space to interrogate the sub-
stantial coverage data available [20–22].
2. Methods
2.1. Study design
This is a descriptive synthesis of data collected as part of a large
study collating lessons learnt from HPV vaccine projects/programmes
in LAMIC [20].
2.2. Country selection
A mapping exercise identiﬁed all low (LIC) and lower-middle in-
come countries (LMIC) that were known to international organisations
to have completed at least six months of a HPV vaccine demonstration
or pilot project or an HPV vaccination national programme by May
2016, all were included in data collection. Data from upper-middle
income countries (UMIC) that had completed demonstration project(s)
in the same time period were also included. In total data were examined
from 45 LAMIC for this study (Table 1; 18 LIC, 22 LMIC, 5 UMIC).
2.3. Deﬁnitions
A ‘demonstration project’ refers to a small-scale project, often limited
to one or two districts or smaller administrative units in a country, and
were deﬁned by the funder and/or implementer and grant award de-
tails, e.g. GAP or Gavi or other funder. A ‘programme’ is a national
vaccination programme. ‘Delivery strategies’ were deﬁned by the vacci-
nation sites used (schools, health facilities, outreach sites) and the
target population (age or school grade). Within each demonstration
project or national programme, if multiple diﬀerent delivery strategies
were piloted or the delivery strategy changed over time, these were
deﬁned as distinct delivery experiences (Supplementary Fig. 1). Countries
often implemented multiple diﬀerent projects/programmes over time
and tested diﬀerent delivery strategies so a country could have a
number of diﬀerent delivery experiences. More information on the
diﬀerent experiences is published elsewhere [20].
Uptake was deﬁned as ﬁrst dose coverage among the target popu-
lation and was analysed alongside ﬁnal dose coverage. Completion was
deﬁned as the proportion of girls who received the ﬁnal dose of the
vaccine schedule among those who had received the ﬁrst dose.
Coverage surveys were deﬁned as surveys that used the WHO coverage
survey guidelines [23] or similar, to assess the vaccination status of the
general population.
2.4. Data collection
Methods are fully described elsewhere [20]. After obtaining in-
formed consent, we conducted interviews over the phone or in person
with key informants (KIs) e.g. EPI managers, HPV coordinators or
equivalent, a systematic search of ﬁve databases for published literature
and solicited unpublished documents including coverage surveys and
country reports. Estimates of coverage results from projects/pro-
grammes were collated from written published and unpublished reports
only. KIs and contacts supplying unpublished data were assured that the
data would be anonymised to garner detailed reports on challenges as
well as successes in implementing HPV vaccine delivery. Data were
extracted onto a template informed by the WHO New Vaccine In-
troduction Guidelines [24]. National primary school enrolment data
from the most recent year available were sourced from the UNESCO
Institute of Statistics data centre [25].
2.5. Analysis
Coverage achievements were analysed descriptively by delivery
experience. Due to the heterogeneity of funder requirements, project/
programme organisation, design, and overall experience, multivariate
analyses of the correlates of coverage were not appropriate. Where
coverage and costing data were available, correlations were described.
Reported coverage is for the selected target group of each distinct de-
livery experience. Where more than one estimate of coverage was
available for the same delivery experience, the data considered to be of
best quality were selected for descriptive analyses, e.g. estimates from
coverage surveys were used wherever possible.
3. Results
A total of 56 KI interviews with representatives from 40 countries
were completed, 188 unpublished documents were received, and 61
published articles and 11 conference abstracts identiﬁed. Lessons learnt
on other topics have been published elsewhere [20–22,26].
3.1. Data availability
As of May 2016, only 17 delivery experiences in 13 countries had
completed and ﬁnalised their coverage survey results (Fig. 1;
Supplementary Fig. 2) [23]. All other coverage data came from ad-
ministrative statistics that divided the reported number of doses ad-
ministered by the estimated target population. Of the 91 distinct de-
livery experiences in 45 countries identiﬁed, 76 experiences (84%)
across 40 LAMICs (89%) provided at least one estimate of uptake,
completion, or ﬁnal dose coverage. Over half (55%) of data were
sourced from unpublished reports obtained from KI interviews for as
there were no published coverage results available. Estimates for the
remaining experiences were obtained from the published literature.
Estimates of uptake were available from 54 experiences in 35
countries and estimates of completion from 54 experiences in 30
countries. HPV vaccine ﬁnal dose coverage estimates were available
from 59 delivery experiences in 33 of the 45 countries [20].
3.2. Data accuracy
Across the 59 delivery experiences contributing ﬁnal dose coverage
data, the 42 administrative coverage estimates were, on average, higher
than the 17 results from actual coverage surveys (Table 3). Only 8
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countries reported both coverage survey results and administrative
coverage data; 3 administrative coverage estimates were within 1% of
the corresponding survey coverage Fig. 2 administrative coverage es-
timates were 6–7% lower than the subsequent coverage survey results,
and 3 administrative coverage estimates were 5–17% higher than the
subsequent survey data.
Reports and interviews indicated that administrative coverage data
were of variable quality for a number of reasons. Census estimates were
commonly used for the application to the vaccine provider in order to
estimate the number of vaccine doses needed in the ﬁrst year of the
demonstration project/programme. However, during microplanning
prior to delivery, challenges in estimating the true vaccine target po-
pulation and therefore vaccine dose distribution to each district/health
facility were experienced by almost all of the 41 countries that provided
some information on uptake, coverage, or completion (Table 2). Ad-
ditionally, where teachers, health-workers and/or community leaders
did not fully understand the eligibility criteria, or could not practically
operationalise it, doses were reportedly often administered to ineligible
girls, e.g. vaccination of any girl over the age of 9 years when the target
population was 9 year-olds only, or vaccination based on girls’ stature
due to lack of age documentation. These challenges resulted in potential
inaccurate estimations of both the number of doses administered to the
target population and the size of the target population itself.
3.3. Coverage survey results
We obtained ﬁnal dose coverage data from 17 coverage surveys in
13 countries; all were conducted after demonstration projects, 13 re-
ported estimates of uptake and 12 reported data on completion. Nine
coverage results from 5 countries were available in the published
Table 1
Countries, projects, programmes approached during data collection.
Country Income Groupa Type of HPV vaccination ﬁnancing Country Income Groupa Type of HPV vaccination ﬁnancing
Bhutan LMIC GAP demo and national programme (donation) Mali LIC GAP and Gavi demos
Bolivia LMIC GAP demo Moldova LMIC GAP demo
Botswana UMIC World Bank (WB), MOH demos and national
programme (MOH)
Mongolia LMIC GAP demo
Brazil UMIC GAP, MOH demos and national (MOH) Mozambique LIC Gavi demo
Burkina Faso LIC Gavi demo Nepal LIC GAP/ACCF demo
Cambodia UMIC GAP demo Niger LIC Gavi demo
Cameroon LMIC GAP and Gavi demos Papua New Guinea LMIC GAP demo
Cote d'Ivoire LMIC Gavi demo Peru UMIC PATH demo and national programme
Ethiopia LIC Gavi demo Philippines LMIC Jhpiego demo
The Gambia LIC Gavi demo Rwanda LIC National introduction (donation and Gavi)
Georgia LMIC GAP demo Senegal LMIC Gavi demo
Ghana LMIC GAP and Gavi demos Sierra Leone LIC Gavi demo
Guyana LMIC GAP demo and national programme Solomon Islands LMIC Gavi demo
Haiti LIC GAP/PIH demo South Africa UMIC demos and national programme
Honduras LMIC GAP demos and national programme (MOH) Tanzania LIC GAP and Gavi demo
India LMIC PATH demo Thailand UMIC Jhpiego demo
Kenya LIC GAP and Gavi demos Togo LIC Gavi demo
Kiribati LMIC GAP/ACCF demo Uganda LIC PATH, GAP, Merck demos and national
programme (Gavi)
Lao PDR LMIC Gavi demo Uzbekistan LMIC GAP demo
Lesotho LMIC GAP demo and national programme Vanuatu LMIC ACCF demo and national programme
Madagascar LIC Gavi demo Vietnam LMIC PATH demo
Malawi LIC Gavi demo Zambia LMIC GAP demo
Zimbabwe LIC Gavi demo
a World Bank classiﬁcation February 2016. Abbreviations: ACCF, Australian Cervical Cancer Foundation; GAP, GARDASIL Access Programme; LIC, low-income country; LMIC, lower-
middle-income country; MOH, Ministry of Health; PIH, Partners in Health; UMIC, upper-middle-income country.
Fig. 1. Coverage survey results (n = 17) from demonstration projects in 13 countries,
plotted against estimates of primary school net enrolment ratios, by delivery strategy. Net
primary school enrolment ratio: The number of children who belong to the age group that
oﬃcially corresponds to that of primary schooling who are enrolled in primary school,
divided by the total population of the same age group.
Fig. 2. Uptake, coverage and completion achievements as documented in coverage sur-
veys and the estimated recurrent ﬁnancial cost of delivery per dose in 5 Gavi demon-
stration projects and 5 other demonstration projects. Recurrent ﬁnancial cost of delivery
per dose is presented as calculated in the source cost analyses. These analyses used dif-
ferent methods but were restricted to reporting costs likely to be ‘recurrent’ at every
vaccination session i.e. not capital costs or start-up costs, and costs that were not already
assumed by the routine immunisation system i.e. not economic costs; e.g. the additional
allowances paid to staﬀ for outreach activities speciﬁc to HPV vaccination were counted
in the recurrent ﬁnancial cost but core staﬀ salaries were not included.
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literature [27–29] and KIs provided 8 coverage estimates from 8 cov-
erage surveys conducted after Gavi demonstration projects. Of the 17
survey results, two were from projects implementing health facility
based delivery strategies [27,28] and the remaining 15 were from
projects that implemented ‘mixed strategies’ that predominantly used
schools as vaccination venues alongside opportunities for vaccination
outside schools, with or without speciﬁc additional community out-
reach (Fig. 1). Aside from one project, all were run with high levels of
involvement from EPI and MOE oﬃcials. No coverage survey data were
available from national HPV vaccine programmes.
The median ﬁnal dose coverage across 17 coverage surveys was
79% (range 52–96%) the median uptake across 13 of the surveys was
88% (range 72–99%). It was possible to calculate 12 estimates of
completion from the surveys with a median of 89% (range 71–94%).
Five of the surveys were after a 2-dose vaccination schedule and 12
were after a 3 dose schedule. There were no diﬀerences in the ﬁnal dose
coverage, uptake or completion rates achieved by vaccine schedule. The
median coverage for the 2 dose schedule was 79% (range 65–93%)
compared with 81.6% for the 3-dose schedules (range 52–96%). Only
two estimates of completion were available for 2-dose schedules (87%
and 88%); 10 were available for 3-dose schedules (median 90%, range
71–94%).
There were no correlations between survey data on ﬁnal dose cov-
erage and the estimated recurrent ﬁnancial costs of delivery from cost
analyses. Cost of delivery was estimated at US$1.11–2.10 per dose for 6
(non-Gavi supported) experiences in 2007–10, where coverage varied
between 61% and 96% [27,30]. The mean recurrent ﬁnancial costs of
delivery from 5 costing analyses performed on Gavi demonstration
projects was US$6.05 per dose (range US$3.10–9.21); the corre-
sponding coverage surveys for 4 of those countries indicated between
62% and 73% coverage (Fig. 2).
3.4. Administrative data
Administrative estimates of ﬁnal dose coverage were available from
42 experiences in 20 countries (median 90%; range 51–105%). Forty-
one delivery experiences in 22 countries provided administrative data
on uptake with a median of 93% (not all of them also provided ﬁnal
dose coverage data; range 64–107%). Delivery experiences in 30
countries provided an estimate of completion, with/without coverage
and uptake data, median 95% (range 70–100%; Table 3).
Projects and programmes contributing administrative data were
highly variable in organisation and evaluation requirements, e.g. some
early GAP demos had little EPI or MOE involvement in project design
and implementation and few formal evaluation requirements.
Administrative coverage data from 8 national programmes were
available; 6 of these achieved ≥ 90% coverage (Table 3). Strategies
involving schools as a vaccination venue predominated and achieved
high coverage (Table 3).
Joint delivery of HPV vaccine alongside another intervention to the
same age group was attempted in 14 delivery experiences. Only 6
supplied administrative data on coverage achievements; 4 experiences
achieved>90% coverage for HPV vaccination (Table 3). Interventions
combined with HPV vaccination included those delivered in existing
school health programmes or Child Health Days and re-introduction of
interventions for this age group such as tetanus toxoid vaccination and/
or deworming. There was little/no evaluation of the correlates of suc-
cess of such strategies.
3.5. Correlates of uptake, completion and ﬁnal dose coverage
As survey data were limited, we combined survey and adminis-
trative data to examine correlates of uptake, completion and coverage.
All delivery experiences in 33 countries achieved more than 50% ﬁnal
dose coverage and almost half (42%) reported 90% or higher coverage
with no trend over time (Table 3; Supplementary Fig. 2).
Even with combined data, only ﬁve estimates from health facility-
based delivery strategies were available; the majority of experiences
implemented school-based (n = 20, 33%) or mixed (n = 35, 58%)
strategies. The predominance of data on delivery strategies using
schools as a vaccination venue informed the analysis of correlates of
good uptake, completion, and ﬁnal dose coverage.
In 15 countries with ≥ 90% primary school net enrolment and
coverage data, there was little diﬀerence in coverage achievements
between those with or without an out-of-school strategy.
Among delivery experiences in countries with 80–89% primary
school enrolment, those with an out-of-school strategy (10/22 experi-
ences) gained a median ﬁnal dose coverage of 95%. (inter-quartile
range 90–98%) while those with no out-of-school strategy (12/22 ex-
periences) had median coverage of 84% (interquartile range 80–92%).
However, KIs reported challenges in identifying out-of-school girls.
Speciﬁc mobilisation strategies for out-of-school girls were needed to
make them aware of local opportunities to receive HPV vaccination. In
addition to the involvement of teachers, where available, community
health workers (CHWs) were reported to have provided a valuable re-
source in many diﬀerent settings, in spreading educational messages
about the vaccine, identifying out-of-school girls and following up girls
who missed doses.
All four countries with less than 80% national primary school net
enrolment and HPV vaccine demonstration project coverage data had
implemented strategies to reach out-of-school girls. Some invited girls
through tailored mobilisation strategies to schools and clinics for
Table 2
Challenges in identifying and enumerating the HPV vaccine target population.
Observation Impact
Challenges in identifying and enumerating the HPV target population in schools
Incomplete Ministry of Education registration of all schools at district level. Exclusion of new/private/religious or unregistered schools in microplanning and headcounts,
resulting in a two-phase delivery of dose 1 as parents/teachers at unregistered schools in the
area came forward later to request the vaccine.
Lack of adequate training/communication Some schools included boys or ineligible girls in their headcounts.
Diﬃculty determining age Stature or grade was used instead.
High rates of absenteeism Inaccurate estimates of school grade populations led to more girls than expected on vaccination
day.
Challenges in identifying and enumerating the HPV target population out of school
Communities with out-of-school girls were generally hard to reach and diﬃcult
to identify.
Some countries used local social workers, community health workers or social enterprise/ NGO
groups but house-to-house outreach was time intensive and expensive unless conducted by
volunteers.
Intense social mobilisation encouraging any out of school girls to go to health
facilities to be vaccinated yielded low coverage in this group.
Estimates of out of school girls were rarely veriﬁed/ validated.
Out of school girls are even less likely to know their age and eligibility. Communication of eligibility criteria in non-interactive social mobilisation e.g. announcements
and posters, needs to be adapted to reference commonly known events in the recent past to aid
parents or guardians to determine age.
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Table 3
All available ﬁnal dose coverage, uptake and completion data by project/programme characteristic.
Characteristic Experiences with data Number (%) of experiences with the following coverage: Median (%; range)
50–59% 60–69% 70–79% 80–89% ≥ 90%
Final dose coverage – administrative data 42 2 (5) 4 (10) 3 (7) 11 (26) 22 (52) 90% (51–105)
Final dose coverage – survey data 17 1 (6) 3 (18) 5 (29) 5 (29) 3 (18) 79% (52–96)
All ﬁnal dose coverage dataa:
Country income groupb
LIC 19 1 (5) 2 (11) 2 (11) 7 (37) 7 (37) 85% (51–105)
LMIC 28 1 (4) 4 (14) 4 (14) 5 (18) 14 (50) 90% (59–100)
UMIC 12 1 (8) 1 (8) 2 (17) 4 (33) 4 (33) 85% (51–98)
Type of project/programme
National programme 8 0 1 (13) 0 1 (13) 6 (64) 92% (65–99)
Demonstration project 51 3 (6) 6 (12) 8 (16) 15 (29) 19 (37) 85% (51–105)
Delivery strategy
School only 20 1 (5) 0 3 (15) 8 (40 8 (40) 86% (51–99)
School + health facility (± outreach) 34 2 (6) 5 (15) 4 (12) 8 (24) 15 (44) 87% (52–105)
Health facility only (± outreach) 5 0 2 (40) 1 (20) 0 2 (40) 73% (65–100)
Joint delivery
Concurrent deliveryc 6 0 2 (33) 0 0 4 (67) 91% (61–98)
None 46 3 (7) 3 (7) 8 (17) 15 (33) 17 (37) 85% (51–105)
Dose schedule
2-dose 9 0 1 (12) 2 (22) 3 (33) 3 (33) 83% (65–98)
3-dose 50 3 (6) 6 (12) 6 (12) 13 (26) 22 (44) 88% (51–105)
Number (%) of experiences with the following uptake: Median(%; range)
50–59% 60–69% 70–79% 80–89% >90%
First dose uptake – administrative data 41 0 1 (2) 3 (7) 12 (29) 25 (62) 93% (64–107)
First dose uptake – survey data 13 0 0 3 (23) 4 (31) 6 (46) 88% (72–99)
All uptake dataa:
Country income groupb
LIC 18 0 0 2 (11) 5 (28) 10 (56) 91% (70–100)
LMIC 25 0 0 3 (12) 8 (32) 14 (56) 94% (73–107)
UMIC 12 0 1 (8) 1 (8) 3 (25) 7 (58) 93% (64–101)
Type of project/programme
National programme 8 0 0 1 (12) 2 (25) 5 (63) 92% (79–98)
Demonstration project 47 0 1 (2) 5 (11) 14 (30) 26 (55) 92% (70–107)
Delivery strategy
School only 18 0 1 (6) 1 (6) 6 (33) 9 (50) 90% (70–100)
School + health facility (± outreach) 32 0 0 5 (16) 8 (25) 19 (59) 92% (72–107)
Health facility only (± outreach) 5 0 0 0 2 (40) 3 (60) 93% (82–101)
Joint delivery
Concurrent deliveryc 7 0 0 2 (29) 1 (14) 4 (57) 92% (72–99)
None 43 0 1 (2) 4 (9) 14 (32) 24 (55) 92% (70–107)
Dose schedule
2-dose 12 0 1 (8) 4 (33) 7 (59) 0 91% (73–100)
3-dose 43 1 (2) 5 (12) 13 (30) 23 (54) 1 (2) 93% (70–107)
Number (%) of experiences with the following completion: Median (%; range)
50–59% 60–69% 70–79% 80–89% >90%
Completion – administrative data 42 0 0 4 (9) 13 (31) 25 (60) 95% (70–100)
Completion – survey data 12 0 0 1 (8) 5 (42) 6 (50) 89% (71–94)
All completion dataa:
Country income groupb
LIC 17 0 0 3 (18) 6 (35) 8 (47) 88% (71–100)
LMIC 26 0 0 1 (4) 10 (38) 15 (58) 91% (70–100)
UMIC 11 0 0 1 (9) 2 (18) 8 (72) 94% (73–100)
Type of project/ programme
National programme 6 0 0 0 1 (17) 5 (83) 97% (80–100)
Demonstration project 48 0 0 5 (10) 17 (35) 26 (54) 90% (70–100)
Delivery strategy
School only 19 0 0 2 (11) 4 (21) 13 (68) 95% (75–100)
School + health facility (± outreach) 30 0 0 3 (10) 10 (33) 17 (57) 90% (70–100)
Health facility only (± outreach) 5 0 0 0 4 (80) 1 (20) 88% (80–100)
Joint delivery
Concurrent deliveryc 6 0 0 0 3 (50) 3 (50) 92% (85–100)
None 40 0 0 3 (7) 12 (30) 25 (63) 92% (70–100)
Dose schedule
2-dose 4 0 0 0 2 (50) 2 (50) 92% (87–98)
3-dose 50 0 0 5 (10) 16 (32) 29 (58) 91% (70–100)
a If more than one coverage estimate was available from the same delivery experience the most reliable data were used e.g. coverage survey data were used when available.
b Excluded the HIC due to requirement for anonymity.
c This includes experiences that delivered another service at the same time as HPV vaccine (to the same age group). Row percentages.
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vaccination at the same time as school-going girls. KIs reported that
outreach activities through ﬁxed/mobile sites in the community and/or
door-to-door vaccine delivery were critical to achieving any uptake in
out-of-school girls. Community health workers (CHWs) aided mobili-
sation of communities prior to arrival of health workers for outreach
sessions. Coverage in areas with low school enrolment was reportedly
inﬂuenced by the diﬃculty of tracing vaccinated girls, with subsequent
low completion rates.
Other factors reported in interviews to have inﬂuenced coverage
included the social mobilisation strategy used, logistical challenges, and
rumours (Table 4) [22]. Delays in vaccine delivery resulted in com-
munities losing interest and were perceived to contribute to low cov-
erage. Delays were prevented with high-level political commitment to
ensure a smooth importation process, timely fund disbursement, and
good inter-sectoral coordination.
KIs reported that achieving good coverage in urban areas was
consistently more challenging than in rural areas as they were more
exposed to negative media and rumours about the vaccine.
Additionally, parents of girls attending private schools in general
needed more information and longer to digest communication materials
before accepting the vaccine compared to parents of girls attending
government schools. The level and intensity of social mobilisation could
vary across the country. In areas where rumours were underestimated,
or not addressed immediately, these had a high impact on coverage
attained and caused at least 3 projects to cease before they had com-
pleted delivering the third dose [22].
4. Discussion
This study built on ﬁndings in the published literature [27–29] by
including substantial additional unpublished data, to form a compre-
hensive synthesis of HPV vaccine coverage achievements in LAMICs.
Between 2007 and 2016, 33 of 45 LAMICs with HPV vaccination ex-
perience had ﬁnal dose coverage data and all attained over 50% cov-
erage in HPV vaccine demonstration projects or national programmes.
These coverage achievements are aligned with, and in some cases ex-
ceed, coverage results from high income countries [31,32]. However,
there remains limited data from national programmes.
The majority of coverage data were administrative estimates; the
advantages and disadvantages of using administrative data to monitor
vaccine projects/programmes have been discussed in the published
literature [33,34]. However, we gained details around the speciﬁc
challenges in the enumeration of the HPV vaccine target population.
Correlates of coverage were remarkably similar across country in-
come groups, geographic regions and types of project/programme. In
agreement with previously published literature, school-based delivery
or a mixed strategy of school and health facility based delivery with/
without outreach were the most common delivery strategies and ob-
tained high coverage [35,36]. There remains little experience and
coverage data from strategies using only health facility-based delivery
[27,28,36].
Findings from KI interviews conﬁrmed and enriched the numerical
data, providing additional insights into the multidimensional factors
inﬂuencing uptake, completion and ﬁnal dose coverage e.g. inter-sec-
toral collaboration, high-level political commitment and the im-
plementation of diﬀerent delivery strategies. The involvement of both
CHWs and community leaders increased acceptance and uptake within
the community as has been reported previously in Rwanda [37].
The comprehensive nature of this study allowed some previously
published ﬁndings to be supported by data from many diﬀerent con-
texts. It has been reported in at least 3 publications that urban com-
munities may attain lower HPV vaccine coverage than rural or tribal
areas [27,38,39].
Limitations include that 32 of the 92 delivery experiences that had
completed at least 6 months of implementation by May 2016 in 12
countries were missing data on ﬁnal dose coverage. Among those de-
livery experiences that reported coverage, 51 were demonstration
projects, of relatively small scale and speciﬁcally designed to attain
good coverage. The majority of data were administrative estimates with
limited ability to assess data accuracy. Experiences that conducted
coverage surveys may have diﬀered in structure and organisation from
those where only administrative data were available.
Coverage achievements did not seem to correlate with cost per dose
delivered; further evaluation of how to optimise delivery strategies to
achieve acceptable coverage at low cost is needed, as this is one of the
key barriers to national introduction. Best practices when only deli-
vering vaccine through health facilities and routine outreach services
and/or during national programmes are not known. Concerns over the
sustainability of the predominantly school-based delivery implemented
in demonstration projects were widespread and are explored in related
publications [20,21,26]. As countries transition away from Gavi ﬁ-
nancial support, policymakers have stated they need data and/or
technical assistance to assess the relative cost and sustainability of
diﬀerent HPV vaccine delivery strategies in order for programmes to
continue.
Table 4
Factors correlated with high and low coverage experiences from KI interviews.
HPV delivery experiences that achieved high/low
ﬁnal dose coverage
Factors correlated with coverage achieved, as reported in key informant interviews
‘High’ coverage (> 75%) • Strategies using schools that also had a good collaboration with the education sector at national and local levels
(there are limited data on health facility only strategies which precludes correlation of factors to ensure their
success).
• Involvement of the national immunisation programme in planning and implementation.• Targeted social mobilisation of out-of-school girls to attend outreach venues for vaccination achieved uptake in this
group, tracing out of school girls to ensure completion was challenging but successful in strategies that used
community health workers and/or local volunteers.
• Comprehensive social mobilisation of the whole community using face-to-face meetings with local ‘credible
inﬂuencers’ (health workers, teachers, religious leaders, community elders).
• Use of vaccination registers and cards aided tracing of girls to ensure completion.• Delivering vaccine on schedule (as communicated during social mobilisation) and within 1 school year (avoiding
school exam time or vacation/harvest periods).
‘Low’ coverage (50–75%) • Ineﬀective coordination and planning with schools, especially in areas of a high-proportion of private schools that
generally needed more time and more intensive mobilisation than government schools.
• Rumours that caused schools to refuse vaccinators.• Urban areas with high exposure to negative media/ mobile populations.• Other factors: Delay in receipt of social mobilisation and school-delivery funds, not providing a second opportunity
for girls who missed the ﬁrst dose.
K.E. Gallagher et al. Papillomavirus Research 4 (2017) 72–78
77
5. Conclusions
High HPV vaccine uptake, completion and ﬁnal dose coverage has
been achieved in demonstration projects and national programmes in
41 LAMICs to date. Data and interviews expose a multitude of factors
that can inﬂuence uptake, completion and ﬁnal dose coverage. Further
good quality data are needed from health facility based delivery stra-
tegies and national programmes to aid policymakers to eﬀectively and
sustainably scale-up HPV vaccination.
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